(Q38758229)

6 September 2017

The Use of Antiepileptics in Migraine Prophylaxis (English)

1 reference

6 September 2017

1 reference

Francesca Bagnato

1

1 reference

PubMed ID

26935348

6 September 2017

Janine Good

series ordinal

2

1 reference

6 September 2017

3 March 2016

1 reference

6 September 2017

1 reference

6 September 2017

56

1 reference

6 September 2017

603-615

1 reference

6 September 2017

3

1 reference

Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention

6 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

The International Classification of Headache Disorders, 3rd edition (beta version)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Migraine: preventive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Migraine is a neuronal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Migraine: the evolution of our knowledge

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Basic mechanisms of migraine and its acute treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Studies on the pathophysiology and genetic basis of migraine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Mechanisms of action of valproate: a commentatory

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Pathophysiological basis of migraine prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Possible mechanisms of valproate in migraine prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Valproate: a new drug in migraine prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Migraine prophylaxis with divalproex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Divalproex sodium in migraine prophylaxis: a dose-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Sodium channel antagonists for the treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Long-term Safety of Depakote in Headache Prophylaxis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcom

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Topiramate modulates habituation in migraine: evidences from nociceptive responses elicited by laser evoked potentials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Topiramate monotherapy in the treatment of newly or recently diagnosed epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Topiramate monotherapy in epilepsy and migraine prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Topiramate in migraine prevention: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Topiramate for migraine prevention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Topiramate in migraine prevention: results of a large controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Subcutaneous histamine versus topiramate in migraine prophylaxis: a double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Increased propensity for calcium phosphate kidney stones with topiramate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Effect of topiramate on acid-base balance: extent, mechanism and effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Topiramate and the vision: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Bilateral simultaneous acute angle closure caused by sulphonamide derivatives: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Pharmacokinetics of topiramate during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Serum concentration/dose ratio of topiramate during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Efficacy of gabapentin in migraine prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Antiepileptics in migraine prophylaxis: an updated Cochrane review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

CADASIL presenting as status migrainosus and persisting aura without infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Acetazolamide efficacy and tolerability in migraine with aura: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Efficacy and tolerability of acetazolamide in migraine prophylaxis: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Levetiracetam in migraine prophylaxis: a randomized placebo-controlled study in a rural medical institute in northern India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Open-label zonisamide for refractory migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Zonisamide for migraine prophylaxis in patients refractory to topiramate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

Perampanel for epilepsy with partial-onset seizures: a pharmacokinetic and pharmacodynamic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEAD.12781

21 January 2018

Identifiers

DOI

10.1111/HEAD.12781

1 reference

6 September 2017

1 reference

PubMed ID

26935348